ArticleApplied biochemistry and biotechnology2026
FAM72A Knockdown Drives Cell Mitophagy and Pyroptosis in Ovarian Cancer Via the PINK1/Parkin Pathway.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study explored the role of Family with Sequence Similarity 72 Member A (FAM72A) in regulating mitophagy and pyroptosis via the PINK1/Parkin pathway in ovarian cancer (OC). Bioinformatics analysis and clinical tissue and cell assays revealed that FAM72A was significantly overexpressed in OC. Silencing FAM72A in OC cells suppressed proliferation, invasion, and migration, while promoting apoptosis. Additionally, FAM72A knockdown increased mitochondrial ROS levels, autophagosome-mitochondria colocalization, and the LC3II/I ratio and reduced p62 expression, mitochondrial membrane potential, and ATP levels in OC cells. Downregulation of FAM72A upregulated PINK1 and Parkin expression and increased the expression of pyroptosis-related markers including NLRP3, ASC, cleaved caspase-1, IL-1β, and IL-18 in OC cells. Furthermore, the inhibitory effect of FAM72A knockdown was reversed by treating cells with mitochondrial inhibitors or by specifically knocking down PINK1. In vivo experiments confirmed that FAM72A promoted tumor growth by inhibiting the PINK1/Parkin pathway. Conclusively, FAM72A knockdown drives mitophagy and pyroptosis in OC by activating the PINK1/Parkin pathway, highlighting its potential as a therapeutic target for OC.
Indexed as
Identifiers
42159844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.